According to the table on slide 8, 3 on placebo achieved cEVR between weeks 10 and 12 raising the percentage from 54 to 71. If only a small percentage of the remaining 15 on placebo achieve cEVR then the placebo percentage would drop. Thats the CEO's argument.
I'm not sure why ANDS decided to present preliminary data that presents the drug in a bad light. They should have waited till all placebo patients had been dosed if they are claiming the drug works.
Market Data 
Markets 
AI
